Molecular analysis of changes in Pseudomonas aeruginosa load during treatment of a pulmonary exacerbation in cystic fibrosis D.W. Reid, R. Latham, I.L.

Slides:

Advertisements

Similar presentations

Multiple reaction monitoring mass spectrometry to identify novel plasma protein biomarkers of treatment response in cystic fibrosis pulmonary exacerbations

Advertisements

Effects of ivacaftor on severely ill patients with cystic fibrosis carrying a G551D mutation Helge Hebestreit, Annette Sauer-Heilborn, Rainald Fischer,

Rapid emergence of a ceftazidime-resistant Burkholderia multivorans strain in a Cystic Fibrosis patient Joshua R. Stokell, Raad Z. Gharaibeh, Todd R.

Achromobacter species in cystic fibrosis: Cross-infection caused by indirect patient-to- patient contact C.R. Hansen, T. Pressler, W. Ridderberg, H.K.

Christopher C. Miller, Christopher A

A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation.

Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patients Yvonne C.W. Yau, Felix Ratjen, Elizabeth Tullis,

How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF? Sarah P. Cohen, David M. Orenstein

H. Grasemann, E. Tullis, F. Ratjen Journal of Cystic Fibrosis

A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children.

Patrick A. Flume, John P. Clancy, George Z. Retsch-Bogart, D

Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study Doug L. Forrester, Alan J. Knox,

D. Worlitzsch, C. Rintelen, K. Böhm, B. Wollschläger, N. Merkel, M

Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint D.R. VanDevanter, A. Yegin, W.J. Morgan,

Eradication of chronic methicillin-resistant Staphylococcus aureus infection in cystic fibrosis patients. An observational prospective cohort study of.

A longitudinal analysis of chronic MRSA and Pseudomonas aeruginosa co-infection in cystic fibrosis: A single-center study Maret L. Maliniak, Arlene A.

Katelyn Krivchenia, Don Hayes, Joseph D. Tobias, Dmitry Tumin

John Widger, Sarath Ranganathan, Philip J. Robinson

The ease of breathing test tracks clinical changes in cystic fibrosis

Impact of antibiotic treatment for pulmonary exacerbations on bacterial diversity in cystic fibrosis T.W.V. Daniels, G.B. Rogers, F.A. Stressmann, C.J.

Increased serum concentration of G-CSF in cystic fibrosis patients with chronic Pseudomonas aeruginosa pneumonia P.Ø. Jensen, C. Moser, A. Kharazmi,

Pulmonary exacerbations in CF patients with early lung disease

Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study Christine Rønne.

Comparison of real time diagnostic chemistries to detect Pseudomonas aeruginosa in respiratory samples from cystic fibrosis patients J.L. Fothergill,

Gerd Döring, Patrick Flume, Harry Heijerman, J. Stuart Elborn

Implementation of European standards of care for cystic fibrosis �� Control and treatment of infection J.S. Elborn, M. Hodson, C. Bertram Journal of.

Vitamin A and lung function in CF

A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation.

Pulmonary nocardiosis in cystic fibrosis

Cytokines in nasal lavages and plasma and their correlation with clinical parameters in cystic fibrosis Marthe S. Paats, Ingrid M. Bergen, Marleen Bakker,

A.H. Gifford Journal of Cystic Fibrosis

Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009 Yolanda P. Lillquist,

Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis Sanja Stanojevic, Valerie Waters, Joseph L.

Physiologic endpoints for clinical studies for cystic fibrosis

Correlation of sweat chloride and percent predicted FEV1 in cystic fibrosis patients treated with ivacaftor Meredith C. Fidler, Jack Beusmans, Paul Panorchan,

Valerie Waters, Eshetu G

Felix Ratjen, Florian Brockhaus, Gerhild Angyalosi

Cytokine gene polymorphisms and severity of CF lung disease

Stenotrophomonas maltophilia in cystic fibrosis: Improved detection by the use of selective agar and evaluation of antimicrobial resistance P. Goncalves-Vidigal,

Pharmacokinetics and sputum penetration of azithromycin during once weekly dosing in cystic fibrosis patients E.B. Wilms, D.J. Touw, H.G.M. Heijerman

Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis Geraint B. Rogers, Lucas R. Hoffman,

Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled.

Australian epidemic strain pseudomonas (AES-1) declines further in a cohort segregated cystic fibrosis clinic Amanda L. Griffiths, Danielle F. Wurzel,

Theresa A. Laguna, Cynthia B. Williams, Kyle R

Alina A. Ionescu, Lisette S. Nixon, Dennis J. Shale

Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005 F.A. Millar, N.J. Simmonds, M.E. Hodson Journal.

Comparison of two tobramycin nebuliser solutions: Pharmacokinetic, efficacy and safety profiles of T100 and TNS Dorota Sands, Ewa Sapiejka, Grzegorz.

Lung clearance index during hospital admission in school-age children with cystic fibrosis Liam Welsh, Christopher Nesci, Haily Tran, Marisol Tomai,

Successful treatment of cepacia syndrome with a combination of intravenous cyclosporin, antibiotics and oral corticosteroids Francis J. Gilchrist, A.

H. White, A.M. Morton, S.P. Conway, D.G. Peckham

J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer

James H. Hull, Rachel Garrod, Timothy B. Ho, Ronald K. Knight, John R

Daniel J. Smith, Gregory J. Anderson, Scott C. Bell, David W. Reid

Voriconazole therapy in children with cystic fibrosis

C. R. Hansen, T. Pressler, K. G. Nielsen, P. Ø. Jensen, T

D.F. Waterhouse, A.M. McLaughlin, C.G. Gallagher

The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation C. Etherington,

Felix Ratjen, Todd Durham, Tomas Navratil, Amy Schaberg, Frank J

Patients with cystic fibrosis and normoglycemia exhibit diabetic glucose tolerance during pulmonary exacerbation Noa Nezer M. Sc, David Shoseyov, Eitan.

Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz Journal of Cystic Fibrosis

Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Increasing resistance of the Liverpool Epidemic Strain (LES) of Pseudomonas aeruginosa (Psa) to antibiotics in cystic fibrosis (CF)—A cause for concern?

Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L

Changing thresholds and incidence of antibiotic treatment of cystic fibrosis pulmonary exacerbations, 1995–2005 Donald R. VanDevanter, Eric P. Elkin,

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial Michael W. Konstan, Patrick A. Flume, Matthias.

Improved early diagnosis of Pseudomonas aeruginosa by real-time PCR to prevent chronic colonisation in a paediatric cystic fibrosis population Elaine.

R. D. Gray, M. Imrie, A. C. Boyd, D. Porteous, J. A. Innes, A. P

Safety assessment of inhaled xylitol in subjects with cystic fibrosis

Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience C.R.

Presentation transcript:

Molecular analysis of changes in Pseudomonas aeruginosa load during treatment of a pulmonary exacerbation in cystic fibrosis D.W. Reid, R. Latham, I.L. Lamont, M. Camara, L.F. Roddam Journal of Cystic Fibrosis Volume 12, Issue 6, Pages 688-699 (December 2013) DOI: 10.1016/j.jcf.2013.03.008 Copyright © 2013 European Cystic Fibrosis Society. Terms and Conditions

Fig. 1 Examples of the three different patterns of change in P. aeruginosa numbers observed with antibiotic treatment; (a) subject 6 experienced a rapid reduction in P. aeruginosa numbers (shaded columns) and sputum purulence (clear columns) by day 3, which was maintained until the end of treatment; (b) subject 7 did not experience any reduction in P. aeruginosa load or sputum purulence (purulence scores not illustrated) with antibiotic treatment during three consecutive exacerbation episodes; (c) subject 1 experienced a reduction in P. aeruginosa load by day 3, but numbers had increased almost back to baseline values by day 8. Subject 7 did not have a pre-exacerbation sample available. Sputum purulence was not scored for subject 1. Journal of Cystic Fibrosis 2013 12, 688-699DOI: (10.1016/j.jcf.2013.03.008) Copyright © 2013 European Cystic Fibrosis Society. Terms and Conditions

Fig. 2 The correlation between sputum purulence and quantitative load of P. aeruginosa in 10 patients followed through a total of 12 exacerbations. Journal of Cystic Fibrosis 2013 12, 688-699DOI: (10.1016/j.jcf.2013.03.008) Copyright © 2013 European Cystic Fibrosis Society. Terms and Conditions

Fig. 3 The correlation between; (a) P. aeruginosa numbers and lung function when stable pre-exacerbation; (b) reduced P. aeruginosa numbers (expressed as a proportion of the numbers present at the onset of PE) and improvements in lung function with intravenous antibiotics and; (c) the proportion of persisting P. aeruginosa and absolute FEV1 at the end of intravenous antibiotic treatment. Only those data from patients who provided sputum samples over more than seven days of treatment are presented. Journal of Cystic Fibrosis 2013 12, 688-699DOI: (10.1016/j.jcf.2013.03.008) Copyright © 2013 European Cystic Fibrosis Society. Terms and Conditions